ArticleAnnals of medicine and surgery (2012)2025
Aggressive basaloid squamous cell carcinoma of the lung in a young patient: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Basaloid squamous cell carcinoma (BSQCC) of the lung is a rare and aggressive subtype of squamous cell carcinoma. It predominantly affects individuals over 60 with a history of tobacco use. This case report highlights the unique presentation of BSQCC in a young, non-smoking patient, emphasizing the need for early and accurate diagnosis. Case presentation: A 32-year-old male presented with a 1-month history of productive cough and dyspnea. Imaging revealed a right middle lobe mass with bronchial wall thickening. Immunohistochemistry confirmed BSQCC (p63 positive, TTF-1 negative). Molecular analysis identified a TP53 mutation and ZMYND8::FOXO1 transcription, which has not been previously described in BSQCC. Despite chemotherapy with carboplatin-paclitaxel followed by a second-line regimen, rapid disease progression ensued, leading to pleural effusion, cardiac tamponade, and fatal cardiac arrest within 2 months. Clinical discussion: This case highlights diagnostic challenges posed by BSQCC, particularly in atypical presentations without standard risk factors. Molecular findings suggest genetic diversity in BSQCC and underscore the potential for novel markers in diagnosis and prognosis. The advanced stage and rapid progression in this patient limited treatment options, demonstrating the critical need for early molecular testing and multidisciplinary care. Conclusion: BSQCC is an aggressive carcinoma requiring prompt diagnosis and treatment. This case underscores the importance of heightened awareness, molecular profiling, and further research to improve outcomes in rare lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.